Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florian M M Baeres

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Cell and Tissue Research|July 12, 2002
The anatomy and innervation of the mammalian pineal glandMorten Møller, Florian M M Baeres
Endocrinology, Diabetes & Metabolism|April 23, 2020
The prevalence of cardiovascular disease by vascular bed and impact on healthcare costs in a large, real-world population with type 2 diabetesWayne Weng, Sheldon X Kong, Rahul Ganguly, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 18, 2015
COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETESMatthew P Gilbert, Michel Marre, Jens Juul Holst, et al.
Drugs & Aging|February 2, 2013
Observational study of once-daily insulin detemir in people with type 2 diabetes aged 75 years or older: a sub-analysis of data from the Study of Once daily LeVEmir (SOLVE)Eddy Karnieli, Florian M M Baeres, Grzegorz Dzida, et al.
Diabetology & Metabolic Syndrome|June 9, 2016
LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differGuy E H M Rutten, Cees J Tack, Thomas R Pieber, et al.
JAMA Cardiology|December 10, 2025
Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate ReductionPaul M Ridker, Florian M M Baeres, Anders Hveplund, et al.
Journal of the American College of Cardiology|March 14, 2020
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart FailureSteven P Marso, Florian M M Baeres, Stephen C Bain, et al.
Lancet (London, England)|May 20, 2021
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trialPaul M Ridker, Matt Devalaraja, Florian M M Baeres, et al.
The New England Journal of Medicine|May 24, 2024
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 DiabetesVlado Perkovic, Katherine R Tuttle, Peter Rossing, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 25, 2013
Hypercoagulation assessed by thromboelastography is neither related to infarct size nor to clinical outcome after primary percutaneous coronary interventionNadia Paarup Dridi, Jacob T Lønborg, Maria D Radu, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Cell and Tissue Research|July 12, 2002
The anatomy and innervation of the mammalian pineal glandMorten Møller, Florian M M Baeres
Endocrinology, Diabetes & Metabolism|April 23, 2020
The prevalence of cardiovascular disease by vascular bed and impact on healthcare costs in a large, real-world population with type 2 diabetesWayne Weng, Sheldon X Kong, Rahul Ganguly, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 18, 2015
COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETESMatthew P Gilbert, Michel Marre, Jens Juul Holst, et al.
Drugs & Aging|February 2, 2013
Observational study of once-daily insulin detemir in people with type 2 diabetes aged 75 years or older: a sub-analysis of data from the Study of Once daily LeVEmir (SOLVE)Eddy Karnieli, Florian M M Baeres, Grzegorz Dzida, et al.
Diabetology & Metabolic Syndrome|June 9, 2016
LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differGuy E H M Rutten, Cees J Tack, Thomas R Pieber, et al.
JAMA Cardiology|December 10, 2025
Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate ReductionPaul M Ridker, Florian M M Baeres, Anders Hveplund, et al.
Journal of the American College of Cardiology|March 14, 2020
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart FailureSteven P Marso, Florian M M Baeres, Stephen C Bain, et al.
Lancet (London, England)|May 20, 2021
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trialPaul M Ridker, Matt Devalaraja, Florian M M Baeres, et al.
The New England Journal of Medicine|May 24, 2024
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 DiabetesVlado Perkovic, Katherine R Tuttle, Peter Rossing, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 25, 2013
Hypercoagulation assessed by thromboelastography is neither related to infarct size nor to clinical outcome after primary percutaneous coronary interventionNadia Paarup Dridi, Jacob T Lønborg, Maria D Radu, et al.
Pageof 2